The full realization of conditionally replicative adenoviruses (CRAds) for cancer therapy has been hampered by the limited knowledge of CRAd function in vivo and particularly in an immunocompetent host. To address this issue, we previously proposed a canine adenovirus type 2 (CAV2)-based CRAd for clinical evaluation in canine patients with osteosarcoma (OS). In this study, we evaluated infectivityenhancement strategies to establish the foundation for designing a potent CAV2 CRAd with effective transduction capacity in dog osteosarcoma cells. The results indicate that the native CAV2 fiber-knob can mediate increased binding, and consequently gene transfer, in both canine osteosarcoma immortalized and primary cell lines relative to previously reported Ad5 infectivity-enhancement strategies. Gene delivery was further enhanced by incorporating a polylysine polypeptide onto the carboxy terminus of the CAV2 knob. This vector demonstrated improved gene delivery in osteosarcoma xenograft tumors. These data provide the rationale for generation of infectivity-enhanced syngeneic CAV2 CRAds for clinical evaluation in a dog osteosarcoma model.
Introduction
Recent advances in conventional tumor therapies have yielded limited improvement in the treatment of cancer. In this regard, the oncolytic mechanism of conditionally replicative adenoviruses (CRAds) has been harnessed to selectively and effectively kill tumor cells while avoiding toxicity in normal tissues. 1, 2 The promise of these agents as a broad cancer therapeutic approach has led to their rapid translation into a number of clinical trials. 3, 4 Although these studies have clearly established the safety associated with the application of CRAds, they have also revealed our limited understanding of the predicates of CRAd efficacy. 5 Human tumor xenografts in immunodeficient mice have been the model of choice to study the effectiveness of CRAd agents. Although informative about the in vivo oncolytic capability of designed replicative adenoviruses to some extent, several limitations exist with this system. First, it is questionable whether these xenograft tumors represent the true architecture of patient tumors.
Immortalized and transformed cell lines employed as substrates in these models can deviate significantly from the native, complex tumor environment. Second, human adenovirus in general does not productively replicate in mouse cells, precluding application of the murine xenograft system as a method to analyze toxicity in nontarget tissues. Consequently, the cotton rat model which is semipermissive for human adenovirus replication has been suggested as a preclinical model for analyzing replication toxicity of human adenovirus. 6 Third, the use of immunodeficient mice to evaluate oncolytic adenoviruses inherently disregards vector interactions with the host immune system, a key phenomenon that may constitute the basis of the rapid clearance and insufficient performance of these agents in patients. 7 Several recent strategies have been developed to address the lack of adequate preclinical models for evaluating CRAds. One approach employs certain permissive murine tumor cell lines grown in immunocompetent animals to study human adenovirus replication. [7] [8] [9] However, the inefficient replication of human adenovirus in these cell lines, as well as the artificial establishment of these tumors as subcutaneous syngeneic grafts, raises concerns as to how well this model supports human adenovirus replication and how accurately the tumor grafts represent their natural human counterparts. An alternative approach that we have pursued is to use syngeneic Ad vectors in their natural host system. In particular, the application of replicative canine adenovirus type 2 (CAV2) in a spontaneous osteosarcoma (OS) dog tumor model addresses the issues of tumor setting and efficient vector replication and oncolysis. In this regard, canine OS resembles human OS on several levels, including male predilection, lesion locale, high-grade histology, and metastatic potential. 10 Moreover, this spontaneous tumor system would permit the evaluation of the immune system influence on the performance of syngeneic oncolytic adenoviruses. This model is also attractive since over 8000 large breed dogs per year in the US present with this neoplasm, offering the opportunity to study a CAV2 CRAd for this disease in a rigorously controlled clinical environment. 11 The utility of this canine model would be greatly limited unless a selective yet potent CRAd agent is applied to the target disease. The design of an effective oncolytic adenovirus relies on a number of parameters, including the use of tumor-specific control elements or mutation compensation strategies to restrict replication to tumor cells. 1 Additionally, the use of infectivity enhancement to achieve transduction via pathways that are independent from the virus's natural infection route may have to be considered should target cell transduction be insufficient through the virus's native receptor. 12, 13 In humans, most cancers express very low levels of the coxsackie-adenovirus receptor (CAR), the primary attachment receptor for human adenovirus type 5, a vector on which all current human CRAds are based. 14, 15 This fact has motivated the development of various genetic capsid modification strategies to augment the infectivity of oncolytic adenoviruses, including incorporation of short peptides (e.g. RGD and polylysine) into the hexon, penton, and fiber-knob. [16] [17] [18] Indeed, such strategies yielded profound improvements in the oncolytic capability of CRAds relative to nonmodified vectors. 19, 20 Recently, more radical modifications based on serotype and xenotype fiber-knob switching have been exploited to achieve enhanced transduction. [21] [22] [23] Furthermore, the ability to place large ligands onto the adenovirus fiber and protein IX by genetic means suggests the possibility of achieving truly retargeted CRAds. [24] [25] [26] Previously, we developed an osteocalcin promoterspecific CRAd based on CAV2. This replicative virus demonstrated efficient replication and oncolytic potential in a variety of dog OS cell lines both in vitro and in a murine xenograft model. 27 Although we successfully applied the osteocalcin promoter to construct an OStargeted CAV2 CRAd, development of infectivityenhanced canine adenoviral vectors is required for efficient transduction of canine cells, and in particular, dog OS cells, which would yield improved oncolysis. In this study, we evaluated a panel of available infectivityenhancement strategies on both immortalized and primary dog OS cells. We applied capsid modified vectors based on the RGD motif, 17 Ad5/3 chimerism, 21 and polylysine 18 to achieve enhanced transduction. Our results indicate that polylysine incorporation onto the carboxy terminus of CAV2 fiber-knob provided the best infectivity enhancement for the transduction of canine OS cells. These data establish the foundation for developing a tumor-specific infectivity-enhanced CAV2 CRAd for evaluation in a syngeneic dog OS model.
Results and discussion

Ad5 and CAV2 receptor levels on canine OS cells
The initial step of adenovirus entry into cells involves attachment of the fiber-knob region onto a primary cellular receptor. 28 For most human subgroup C adenoviruses, including Ad2 and Ad5 on which most conventional adenoviral vectors are based, the primary receptor has been identified as the CAR. 29 Although CAV2 binds directly to soluble recombinant human CAR and can utilize human or murine CAR for cell entry in vitro, CAV2 also has the ability to transduce CAR-deficient cells, 23, 30 suggesting the possible existence of a second receptor for CAV2. Owing to incomplete understanding of CAV2 cellular entry, and lack of antibodies against the CAV2 receptor, we analyzed CAV2 receptor levels on canine OS cells using a fluorescence-based flow cytometry-binding assay. We applied our recently developed genetic adenovirus-labeling system 31 to label CAV2 virions with pIX-EGFP. Specifically, CAV2-wt-IX-EGFP was constructed from the wild-type Toronto strain A 26-61 CAV2 genome (pTG5412). 32 It contains IX-EGFP (EGFP carboxy terminus fusion) in place of the native IX gene (Figure 1a ). Using our green fluorescent CAV2 vector along with the pIX-EGFP-labeled Ad5 virus. 31 we could functionally analyze the respective receptor levels , and D22), and three primary canine OS cell lines (P-0, P-1, and P-2). Cell suspensions were incubated with saturating levels of virus (10 000 vp/cell) at 41C for 1 h to allow binding but not internalization. Following three wash cycles, the cells were directly analyzed by flow cytometry using EGFP detection as an index of virus binding. Similar to our previous data, Ad5-wt-IX-EGFP bound to A549 cells but not to CHO cells (Figure 2a ). 31 Interestingly, both A549 and CHO cells were highly susceptible to CAV2-wt-IX-EGFP attachment. CAV2-wt-IX-EGFP interacted well with MDCK cells, a positive binding control for this virus, while Ad5-wt-IX-EGFP did not. In addition, CAV2-wt-IX-EGFP demonstrated cell surface attachment to all three established canine OS cell lines, ranging from modest interaction with CF11.T cells to strong binding to D17 and D22 cells. In all three primary cell lines, CAV2-wt-IX-EGFP showed a lesser degree of binding with some shift in the shape of the curve. It should be noted that these cells were highly autofluorescent as indicated by the wide and rather flat fluorescence distribution of nontreated cells. For all established and primary canine OS cells except D17, Ad5-wt-IX-EGFP demonstrated poor cell surface binding. Taken together, these results suggest that (1) all primary canine OS cells and CF11.T displayed modest levels of the CAV2 receptor, (2) D17 and D22 showed relatively strong levels of the CAV2 receptor, and (3) all canine OS cell lines except D17 were deficient in the Ad5 primary receptor, CAR (Figure 2a) . The final observation corresponds with previously published data with respect to CAR deficiency in human OS cells 33 although other studies have indicated contrasting results. 34, 35 Worthy of discussion is the fact that these data strongly support the existence of a second CAV2 receptor which was implied by previous studies. 23, 30 In particular, CHO cells which are known to be CAR negative 31, 36 demonstrated strong CAV2-wt-IX-EGFP binding in our experiments. In situations where Ad5-wt-IX-EGFP showed no binding (all except A549 and D17) or positive binding (A549 and D17), CAV2-wt-IX-EGFP showed distinct binding or much stronger binding, respectively. In addition, blocking with nonlabeled Ad5-wt could not effectively abrogate CAV2-wt-IX-EGFP binding in D17 ( Figure 2b , middle panel), MDCK ( Figure 2b , right panel), and D22 (data not shown) cells; however, CAV2-wt was able to completely block Ad5-wt-IX-EGFP binding in D17 (Figure 2b , left panel) and A549 cells (data not shown). These blocking data indicate that although CAV2-wt could completely prevent Ad5-wt-IX-EGFP binding to CAR, CAV2-wt-IX-EGFP was able to circumvent Ad5 blocking by attaching to a receptor that is likely different from CAR.
The results of this binding assay are based on pIXlabeled Ad5 and CAV2 viruses. Differences in capsid proteins other than the knob region, particularly the presence of an RGD motif in the penton base of Ad5 but not CAV2, 30 may contribute to the distinct binding character of these two viruses. However, the ability of CAV2-wt (lacking penton RGD) to completely hinder Ad5-wt-IX-EGFP binding to CAR and the inability of Ad5-wt (containing penton RGD) to successfully deter CAV2-wt-IX-EGFP binding suggest that the major determinant of attachment in our experiments was mostly mediated by Ad5 and CAV2 knob interaction with their receptor(s). Another consideration that cannot be excluded with our data is the possibility that the CAV2 knob binds to CAR with higher affinity than the Ad5 knob. However, strong binding of CAV2-wt-IX-EGFP and not Ad5-wt-IX-EGFP to CAR-negative CHO cells suggest another interaction mechanism distinct from CAR. Although we demonstrated positive binding of CAV2-wt-IX-EGFP to CHO cells, a previous report noted poor transduction of CHO cells by a CAV2 vector which may be explained by poor internalization and not necessarily poor binding. 30 
Visualization of virus binding on primary canine OS cells
As noted above, the primary canine OS cells were highly autofluorescent, possibly precluding proper detection of virus binding by flow cytometry. To determine virus binding more clearly, we used our green fluorescent adenoviruses to directly visualize virus binding on these cells. Cells plated on glass coverslips were incubated with either Ad5 or CAV2 pIX-EGFP-labeled virus in excess (10 000 vp/cell) for 1 h at 41C and then washed prior to fixation and Hoechst staining. Following a final wash, the coverslips with cells were mounted and sealed on glass slides for imaging. Fluorescence microscopy revealed the highly autofluorescent nature of these cells (white arrows, Figure 3 ). Despite the strong background, green fluorescent viral particles could be distinguished (orange arrows), showing apparent differences in Ad5-wt-IX-EGFP versus CAV2-wt-IX-EGFP binding on these cells. For all three primary OS samples, few cells had attached Ad5-wt-IX-EGFP particles in contrast to CAV2-wt-IX-EGFP, which bound to these cells in either appreciable or overwhelming abundance. These data confirm the availability of the CAV2 receptor(s) on primary OS cells and therefore the ability of a canine adenoviral vector to bind to these cells.
Gene transfer correlates with virus binding
Successful adenoviral entry and resulting gene delivery into cells rely not only on initial attachment to the cell surface via fiber-knob interaction with a receptor but also subsequent steps, including penton base interaction with heterodimeric integrins for endocytosis, 37, 38 escape from endosomes, [39] [40] [41] intracellular trafficking, 42, 43 and DNA transport into the nucleus. 41, 44 The results of our cell-surface virion attachment assay confirmed that a canine adenovirus-based vector could achieve the first step of entry into canine OS cells more efficiently than a human Ad5 vector. Whether these results correspond to effective gene delivery was examined by analyzing luciferase reporter gene expression after transduction of canine OS cells. For this assay, we elected to use isogenic vectors based on the human Ad5 genome displaying either the Ad5 knob or the CAV2 knob. 23 Using a common vector structure would standardize all conditions including the reporter expression cassette and capsid structure while allowing analysis of gene transfer Infectivity enhancement for adenoviral transduction LP Le et al efficacy due solely to variation of the knob. In all cells examined (CF11.T, D17, D22, P-0, P-1, and P-2), the canine knob-based vector, Ad5Luc1-CK, yielded significantly greater gene transfer versus wild-type knobcontaining Ad5Luc1, ranging from roughly seven-fold 
Infectivity-enhanced vector binding/internalization into canine OS cells
Despite the ample transduction of canine OS cells obtained with an adenoviral vector containing the CAV2 knob, we explored the possibility of achieving even greater gene transfer with an array of infectivity enhancement approaches, namely RGD-4C modification of the Ad5 knob HI-loop, 17 serotype switching of the Ad5 knob with that of Ad3, 21 and polylysine incorporation onto the carboxy terminus of both the Ad5 18 and CAV2 fiber knobs. These CAR-independent transduction strategies would redirect the binding of the adenovirus to integrins (Ad.RGD), the Ad3 receptor (Ad5/3Luc1, putatively identified to be CD80 and CD86 36 and/or CD46 45 ), and heparin sulfate proteoglycans (Ad5.pK7 and Ad5Luc1-CK.pK7), respectively. All of these strategies have demonstrated increased gene transfer into various human cancer cell lines that are refractory to Ad5 transduction. To determine the capacity of these viruses to transduce canine OS cells, we performed a DNAbased virus binding/internalization assay. Cells plated 1 day earlier on 24-well plates were incubated with the viruses for 1 h at 371C. Noninteracting viruses were washed away leaving cells containing bound and internalized viruses for processing of total cellular and viral DNA. Real-time quantitative PCR was used to assess the number of bound/internalized adenoviral genome copies using E4-specific primers. The RGDmodified knob improved binding/internalization up to a half-log factor above the unmodified knob (Po0.001 except in the case of D17, P ¼ 0.10) while that of the Ad5/ 3 chimeric knob was poor relative to the other modifications (Po0.04 except compared to the RGD knob in P-0 cells, P ¼ 0.08) and the native Ad5 knob (Po0.002 except in P-0 cells where P ¼ 0.50). The Ad5Luc1-CK and Ad5Luc1-CK.pK7 vectors showed better results when compared to vectors displaying a wild-type Ad5 knob (Po0.02 and Po0.001, respectively, in all cells except D17 where P ¼ 0.17 and 0.27, respectively) or Ad5.RGD knob (Po0.04 for Ad5-Luc1-CK except in P-0 cells where P ¼ 0.47, and Po0.004 for Ad5Luc1-CK.pK7 except in D17 cells where P ¼ 0.06). The outcome of the assay indicates that both the Ad5.pK7 and Ad5Luc1-CK.pK7 viruses achieved similar levels of cellular interaction in D17 and P-0 cells (P ¼ 0.53 and 0.50, respectively) although the latter vector showed better results in CF11.T and D22 cells (Po0.005). At least a six-fold Infectivity enhancement for adenoviral transduction LP Le et al improvement in binding/internalization was observed in all cells (Po0.009 for both vectors) except D17 relative to Ad5Luc1 (P ¼ 0.29 for Ad5.pK7 and P ¼ 0.27 for Ad5Luc1.CK.pK7). It should be noted that D17 cells are relatively CAR positive (Figure 2 ), which likely explains the minor binding/internalization enhancement observed with D17 when using the infectivity-enhanced viruses.
Enhanced gene transfer in canine OS cells
Improved gene delivery due to the various infectivityenhancement strategies was confirmed by luciferasebased gene transfer assays. Data from the above analysis suggest the potential of the pK7 vectors to achieve better transduction of canine OS cells than the other adenoviral vectors used in this study. Indeed, the results obtained from the gene transfer assays were consistent with this prediction. In all cases, the Ad5Luc1-CK.pK7 vector consistently achieved enhanced transduction above the control Ad5 vector, ranging from a 27-fold increase in CF11.T cells to 1867-fold increase in D22 cells ( Figure 6 ). The CAV2 knob alone also conferred appreciable augmentation in gene transfer which was close to (or more than) one-log factor higher than the Ad5 vector. Relative to the Ad5Luc1-CK vector, the Ad5Luc1-CK.pK7 vector was at least four times better in its gene transfer efficacy in CF11.T cells (P ¼ 0.002) and more than 100 times better in D22 cells (P ¼ 0.0009). The results with the Ad5.pK7 vector in general were not as striking as those with the Ad5Luc1-CK.pK7 vector (Po0.03 except in P-0 cells in which Ad5.pK7 showed higher infectivity enhancement, P ¼ 0.0005). Specifically in CF11.T, D22, and P-0 cells, respectively, 15-fold, 16-fold, and 1183-fold infectivity enhancement over the Ad5 virus was observed although no increase was seen in CAR-positive D17 cells. Relative to other fiber modifications, RGD incorporation into the HI loop of the Ad5 knob provided only a slight improvement in gene delivery which was less than an order of magnitude above unmodified Ad5 in most cases except D22 cells (more than 11-fold higher).
Worthy of discussion are some discrepancies noted between the binding/internalization data and the gene transfer results. Although both Ad5.pK7 and Ad5Luc1-CK.pK7 showed nearly the same level of binding/ internalization in D17 and P-0 cells (Figure 5 ), Ad5-Luc1-CK.pK7 demonstrated almost 2 orders of magnitude greater fold enhancement in gene transfer than Ad5.pK7 in D17 cells but more than 1 order of magnitude less gene transfer than Ad5.pK7 in P-0 cells (Figure 6 ). The difference in gene transfer between these two vectors is likely due to dissimilarity in their fiber knobs since the other capsid proteins, particularly the penton base and the fiber-shaft, of the two vectors are identical. Since the attachment/internalization between the two vectors appear to be similar, difference in intracellular trafficking as a consequence of the Ad5 and CAV2 knobs may explain the discrepancy in the gene transfer results. Likewise, previous reports have alluded to the role of the adenovirus fiber-knob in affecting intracellular viral trafficking and consequently gene transfer. [46] [47] [48] In addition, differences in cellular factors between D17 and P-0 cells may also contribute to the same phenomenon. Similar discrepancies were also noted between AdLuc1-CK and AdLuc1-CK.pK7 in CF11.T, D17, and D22 cells.
In vivo gene transfer
Applying Ad5Luc1-CK.pK7 which demonstrated the most significant gene transfer capability in vitro, we tested whether its enhanced gene delivery would be maintained in an in vivo setting. D22 dog OS xenograft tumors in nude mice were injected with the Ad5Luc1-CK.pK7 vector on the right side while the control, Among the vectors evaluated in this study, adenovirus displaying the Ad3 knob in place of the Ad5 knob showed the poorest binding/internalization and infectivity that was significantly lower than the unmodified Ad5 vector. Likewise an Ad vector containing both an Ad3 knob and Ad3 shaft, 51 produced similar results on the cells tested (data not shown). These findings differ from those obtained in other studies which revealed considerable gene transfer augmentation via the Ad3 knob in the context of ovarian, [51] [52] [53] renal, 54 head and neck, 55 skin, 56 and gastrointestinal 20 cancers. Important to note also is the fact that these are epithelial-derived neoplasms (carcinomas) rather than mesenchymal (sarcomas). Similar to the results in this study, certain other cancers have shown minor or no improvement in gene delivery with the Ad5/3 chimeric vector, including glioma, cervical cancer, and non-small-cell lung cancer. 57 The lack of infectivity enhancement observed with the Ad5/3 chimeric vector in our panel of canine cells could simply be due to absence of the putative Ad3 receptor or the fact that the human Ad3 knob cannot effectively interact with the canine counterpart of its human receptor. If the former argument holds true, the striking differences in transduction between the Ad5Luc1-CK vector versus the Ad5/3 chimeric vector support previous findings that CAV2 may enter cells independently of the Ad3 receptor. 23, 30 The enhanced transduction in canine OS cells seen in this study with the CAV2 knob-based vectors relative to an Ad5 knob-based vector may be a species-specific phenomenon. In other words, canine adenovirus may naturally enter canine cells better than human adenovirus. If this were the case, then the converse reasoning that human adenovirus transduces human cells better than canine adenovirus should be true. However, from our observations as well as others, adenoviral vectors with the canine knob routinely yield more efficient gene transfer than vectors with the Ad5 knob not only in canine cells but also in human cells. 23 In fact, transduction of MG63 human OS cells was close to a log factor higher with the CAV2 chimeric adenovirus than a conventional Ad5 vector (data not shown).
We have shown herein that a pIX-EGFP-labeled CAV2 vector demonstrated enhanced cell surface attachment to both established and primary canine OS cells. This improved cell binding translated into increased gene transfer capability with a chimeric Ad5 vector containing the CAV2 knob. An Ad5 recombinant adenovirus containing the CAV2 knob with a carboxy-terminal polylysine peptide consistently showed high gene expression relative to other Ad5 knob-based vectors as well as a vector displaying the unmodified CAV2 knob. The polylysine CAV2 knob-based Ad5 vector also showed enhanced gene transfer in vivo in dog OS xenograft tumors. These data establish the foundation for rational development of an infectivity-enhanced CAV2 CRAd with efficient transduction of canine OS cells. Evaluation of this syngeneic vector in a controlled clinical trial with dog OS candidates would yield informative results with regard to toxicity and the interplay between the host immune system and the replicative agent. Such knowledge is required for advancing the field of oncolytic adenovirus for cancer therapy.
Materials and methods
Cell culture
Human embryonic kidney 293 (American Type Culture Collection (ATCC), Manassas, VA, USA), human embryonic retinoblast 911, 58 human lung adenocarcinoma A549 (ATCC), CHO, canine OS D17, D22, and CF11.T (ATCC), and dog kidney DK and MDCK (ATCC) cells were maintained according to the suppliers' protocols. All three canine primary OS cells (Scott-Ritchey Research Center, Auburn University, Auburn, AL, USA) were maintained in RPMI 1640 medium supplemented with 20% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and penicillin/streptomycin (1000 IU and 1000 mg/ml, respectively). Cells were incubated at 371C and 5% CO 2 under humidified conditions.
Recombinant adenoviruses
All viruses were constructed by homologous recombination in Escherichia coli.
59 Both Ad5-wt-IX-EGFP 31 and CAV2-wt-IX-EGFP 60 are described in detail elsewhere. Ad5.RGD and Ad5.pK7, 18 Ad5/3luc1, 51 and Ad5Luc1-CK 23 along with their isogenic unmodified controls have been previously reported. Note that the gene transfer assay results for these vectors are expressed as fold enhancements relative to their isogenic controls since one common control vector applicable to all of the modified vectors was not available.
Construction of Ad5Luc1-CK.pK7 is described as follows. Plasmid pSHAFT, a cloning plasmid containing the Ad5 fiber gene with the knob region deleted and replaced by a small linker containing SmaI and EcoICR1 restriction sites, 21 was linearized by EcoICR1 digestion (GAG/CTC), leaving two blunt ends. A blunt-ended double-stranded 59-bp linker, encoding five glycineserine repeats followed by seven lysine residues, a stop codon, and poly-adenylation sequences (underlined), was ligated into linearized pSHAFT. The linker oligonucleotides sequence was: (sense) 5 0 -C GCT TCA GGA TCA GGT TCA GGG AGT GGC TCT AAA AAG AAG AAA AAG AAG AAG TAA TAAA-3 0 and (antisense) 5 0 -TTTA TTA CTT CTT CTT TTT CTT TTT AGA GCC ACT CCC TGA ACC TGA TCC TGA AGC G-3 0 . In the resulting plasmid, pSHAFT.pK7, the EcoICR1 site was deleted by insertion of the 59-bp linker, and replaced with an AfeI restriction site (AGC/GCT) resulting from the last two nucleotides of pSHAFT and the first four nucleotides of the linker (bold).
The 536-bp fiber-knob domain of CAV2 was amplified from pTG5412, which contains the complete CAV2 genome (strain Toronto A 26/61) 32 using the following primers: (fwd) 5 0 -TGTGGACTGGGCCTGGCCCTAG CAT-3 0 and (rev) 5 0 -TTGATTTTCGCCTACATAGGTAA-3 0 . This CAV2 knob PCR product lacks the endogenous stop codon (TAA). The blunt-ended CAV2 knob domain PCR product was ligated into SmaI-AfeI-digested pSHAFT.pK7 resulting in pSHAFT-CAV2.pK7. The pSHAFT-CAV2.pK7 plasmid contains the chimeric fiber gene encoding the complete Ad5 fiber-shaft in frame with the CAV2 knob domain, five glycine-serine repeats, and seven-lysine motif followed by a stop codon and poly-adenylation sequence at the 3 0 end. The chimeric fiber gene in pSHAFT-CAV2.pK7 was digested with NcoI and MfeI to liberate a 764-bp DNA fragment containing the carboxy terminus of the shaft, the CAV2 knob domain, and lysine motif, and was ligated into the NcoI-MfeI-digested shuttle vector pNEB.PK.3.6, 21 resulting in pNEB.PK.3.6-CAV2.pK7.
Recombinant Ad5 genomes containing the chimeric CAV2 fiber gene were derived by homologous recombination in E. coli BJ5183 with SwaI-linearized rescue plasmid pVK700 61 and the fiber-containing PacI-PmlIfragment of the shuttle vector pNEB.PK.3.6-CAV2.pK7 described above. pVK700 was derived from pTG3602, 62 but contains an almost complete deletion of the fiber gene and contains a firefly luciferase reporter gene driven by the cytomegalovirus immediate early promoter in place of the E1 region. Genomic clones were sequenced and analyzed by PCR prior to transfection into 293 cells.
Virus propagation and purification
All replication-defective human Ad5-based expression vectors were propagated in E1-complementing 293 cells. Replication-competent Ad5-wt-IX-EGFP was amplified in A549 cells while CAV2-wt-IX-EGFP was propagated in DK cells. Viruses were purified by double cesium chloride (CsCl) ultracentrifugation and dialyzed against phosphate-buffered saline with Mg 2+ , Ca
2+
, and 10% glycerol. Final aliquots of virus were analyzed for viral particle titer (absorbance at 260 nm) using a conversion factor of 1 OD ¼ 10 12 viral particles per ml.
Flow cytometry virus-binding assay
All steps were carried out with 1% BSA/PBS buffer. Cells (2.5 Â 10 5 ) in 200 ml buffer were shaken at 41C with Adwt-IX-EGFP or CAV2-wt-IX-EGFP (10 000 vp/cell). After incubation with the viruses for 1 h, the cells were washed three times with buffer and then analyzed by flow cytometry with EGFP detection. Gates were set according to data obtained for cells not incubated with virus. For blocking experiments, 10-fold excess nonlabeled viruses (10 5 vp/cell Ad5-wt or CAV2-wt viruses) were incubated with the cells for 30 min prior to addition of the labeled viruses for another hour as described above.
Visualization of virus binding on primary OS cells
Primary canine OS cells (2 Â 10 5 ) were plated on glass coverslips (Fisher Scientific, Pittsburg, PA, USA) in sixwell plates with growth medium lacking phenol red (5% FBS/DME medium, Mediatech, Herndon, VA, USA). On the following day, the cells were incubated for 1 h at 41C with Ad5-wt-IX-EGFP or CAV2-wt-IX-EGFP (10 000 vp/ cell) in 500 ml of growth medium supplemented with 25 mM Hepes buffer. After three washes with the above medium to remove unbound virus, Hoescht 33 342 staining (2 mg/ml, Molecular Probes, Eugene, OR, USA) was performed for 5 min in 500 ml of growth medium, and the cells were washed again three times. The cells were fixed onto the glass for 5 min in 3% formaldehyde (Tousimis, Rockville, MD, USA) and then washed again three times. The coverslips were mounted onto glass slides (Fisher Scientific, Pittsburg, PA, USA) using gel mount medium (Biomeda, Foster City, CA, USA). Images of bound viruses were acquired using epifluorescence microscopy with an inverted IX-70 microscope (Olympus, Melville, NY, USA) equipped with a Magnifire digital CCD camera (Optronics, Goleta, CA, USA). Images were acquired with a Â 100 objective using oil immersion and digitally deconvoluted with Iris version 4.15a (http://www.astrosurf.com/buil/) using the Richardson-Lucy algorithm with 15 iterations. EGFP and Hoechst stain images were finally merged using Adobe Photoshop 7.0 (San Jose, CA, USA).
Gene transfer assays
To determine gene transfer efficiency, cells were seeded in a 24-well plate (3 Â 10 4 per well). The next day, the respective cells were infected with the various vectors at 10 vp/cell for 1 h at 371C and then washed once with 10% growth medium. Luciferase activities of cell lysates were measured 48 h later using the Promega luciferase assay system (Madison, WI, USA). Experiments were performed in triplicates with error bars representing s.d. from the mean.
Taqman real-time quantitative PCR binding/ internalization assay
All steps were carried out with 5% DMEM growth medium. Cells (5 Â 10 4 per well in a 24-well plate) were incubated in 500 ml of medium containing the respective viruses (100 vp/cell). After 1 h incubation at 371C, the cells were washed three times with Hank's buffer, collected for total DNA preparation (QIAamp DNA Blood Mini Kit, QIAGEN), and then quantitated using Taqman quantitative real-time PCR with viral E4-specific primers (LightCyclert System, Roche Applied Science, Indianapolis, IN, USA). The experiment was performed with triplicate samples. 9 vp in 25 ml total volume), and the right tumors were injected with Ad5Luc1-CK.pK7 (also 5 Â 10 9 vp in 25 ml total volume). At 4 days after virus administration, the mice were imaged noninvasively for luciferase gene expression. In vivo detection of luciferase gene expression was performed with a custom-built optical imaging system. Briefly, a cryogenically cooled (À1201C, backilluminated Princeton Instruments VersArray:1 KB digital CCD camera (Roper Scientific, Trenton, NJ, USA) with a liquid nitrogen autofill system was mounted on top of a light-tight enclosure. The camera was coupled with a 50 mm Nikkor f/1.2 lens (Nikon, Melville, NY, USA) for image acquisition. Each mouse was anesthetized with 2% isoflurane gas at a flowrate of 0.5-1 l/min (Highland Infectivity enhancement for adenoviral transduction LP Le et al Medical Equipment, Temecula, CA, USA) and then injected with D-luciferin (3 mg in 100 ml, Nanolight Technology, Pinetop, AZ, USA). At 3 min after substrate administration, 60 s exposure images (without binning and at f/1.2) of each mouse were acquired with the WinView/32 software (Roper Scientific). An image was also taken of the mouse body at f/16 for 0.05 s under ambient lighting. Index color image overlays were generated in Photoshop CS2 (Adobe, Seattle, WA, USA) using the segmentation or thresholding parameters determined in ImageTool 3.0 (The University of Texas Health Science Center in San Antonio, TX, USA). Signal intensities are presented in relative light units (RLU). Signal over the entire tumor was quantitated in terms of integrated density (product of mean RLU and the pixel area) with ImageTool.
In vivo imaging of gene expression
Statistical analysis
All P-values for significance between various groups were calculated with single factor analysis of variance (ANOVA). Significance was assumed if Po0.05.
